Strategies for the development of drugs targeting novel coronavirus 2019-nCoV

Yaoxue Xuebao

Volumn 55, Issue 2, 2020, Pages 181-188

  Liu, Qian Yong ^a   Wang, Xiao Liang ^b  

^a Tayu Huaxia Biotech Medical Group Co   (China)

^b INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Combination therapy; Kaletra; Novel coronavirus 2019 nCoV; Novel coronavirus pneumonia; Remdesivir; Targeted therapy

Indexed keywords

GLYCOPROTEIN; MEMBRANE PROTEIN; REMDESIVIR; RNA POLYMERASE;

ANTIVIRAL THERAPY; BIOINFORMATICS; CORONAVIRUS DISEASE 2019; DRUG EFFICACY; DRUG REPOSITIONING; DRUG SCREENING; HUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2;

EID: 85092076065     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: 10.16438/j.0513-4870.2020-0106     Document Type: Review

References (32)

1. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States [J]. N Engl J Med, 2020, l:oa2001191.
2. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses [J], Sci Transl Med, 2017.DOI:10.1126/scitranslmed.aal3653.
3. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro [J]. CeU Res, 2020. DOI: 10.1038/s41422-020-0282-0.
4. Mulangu S, Dodd LE, Davey RT, et al. A Randomized, controlled trial of ebola virus disease therapeutics [J]. N Engl J Med, 2019,381:2293-2303.
5. A phase 3 randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of remdesivir in hospitalized adult patients with mild and moderate 2019-nCoV respiratory disease [ED/OL]. ClinicalTrials.gov Identifier: NCT 04252664. https://www.clinicaltrials.gov.
6. A phase 3 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of remdesivir in hospitalized adult patients with severe 2019-nCoV respiratory disease [ED/OL]. ClinicalTrials.gov Identifier: NCT 04257656. https://www.clinicaltrials.gov.
7. Chu CM, Cheng VCC, Hung IFN, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings [J]. Thorax, 2004,59: 252-256.
8. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection [J]. Drugs, 2003, 63: 769-802.
9. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [J]. Lancet, 2020. DOI: 10.1016/S0140-6736(20)30211-7.
10. Diagnosis and treatment schemes for new coronavirus infection (trial version 4) [ED/OL]. 2020-01-27. http://www.nhc.gov.cn.
11. Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern [J]. Lancet, 2020. DOI: 10.1016/ S0140-6736(20)30185-9.
12. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV [J]. Nat Commun, 2020, 11:222.
13. Zumla A, Chan JF, Azhar EI, et al. Coronaviruses - drug discovery and therapeutic options [J]. Nat Rev Drug Discov, 2016, 15: 327-347.
14. Chan KH, Kao RY, To KK, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus [J]. J Infect, 2013,67:606-616.
15. Cheng KW, Cheng SC, Chen WY, et al. Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus [J]. Antiviral Res, 2015,115:9-16.
16. Olschlager S, Neyts J, Gunther S. Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus [J]. Antiviral Res, 2011,91: 89-93.
17. Mastrangelo E, Pezzullo M, De Burghgraeve T, et al. Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug [J]. J Antimicrob Chemother, 2012,67:1884-1894.
18. Coughlin MM, Prabhakar BS. Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential [J], Rev Med Virol, 2012,22:2-17.
19. O'Keefe BR, Giomarelli B, Barnard DL, et al. Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae [J]. J Virol, 2010,84:2511-2521.
20. Wilson L, Gage P, Ewart G. Hexamethylene amiloride blocks E protein ion channels and inhibits coronavirus replication [J]. Virology, 2006,353:294-306.
21. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin [J]. Nature, 2020. DOI: 10.1038/s41586-020-2012-7.
22. Li W, Moore MJ, Natalya Vasilieva N, et al. Angiotensinconverting enzyme 2 is a functional receptor for the SARS coronavirus [J]. Nature, 2003,426:450-454.
23. Huentelman MJ, Zubcevic J, Prada J, et al. Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor [J]. Hypertension, 2004,44:903-906.
24. Han DP, Penn-Nicholson A, Cho MW. Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor [J]. Virology, 2006,350:15-25.
25. de Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture [J]. Antimicrob Agents Chemother, 2014, 58:4875-4884.
26. Burkard C, Verheije MH, Haagmans BL, et al. ATP1A1-mediated Src signaling inhibits coronavirus entry into host cells [J]. J Virol, 2015,89:4434-4448.
27. Talukdar R, Tandon RK. Pancreatic stellate cells: new target in the treatment of chronic pancreatitis [J]. J Gastroenterol Hepatol, 2008,23:34-41.
28. Cohen J. Can an anti-HIV combination or other existing drugs outwit the new coronavirus? [J]. Science, 2020. DOI: 10.1126/ science.abb0659.
29. Zhou Y, Vedantham P, Lu K, et al. Protease inhibitors targeting coronavirus and filovirus entry [J]. Antivir Res, 2015,116: 76-84.
30. Li H, Wang YM, Xu JY. Potential antiviral therapeutics for 2019 Novel Coronavirus [J]. Chin J Tuberc Respir Dis, 2020. DOI: 10.3760/cma.j.issn. 1001-0939.2020.0002.
31. Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease [J]. mBio,2018,9:e00221-18.
32. Project Bioshield Act [ED/OL]. https://en.wikipedia. org/wiki/ Project_Bioshield_Act.